The pharmacokinetic/pharmacodynamic pipeline: Translating anticancer drug pharmacology to the clinic

AAPS Journal

Volumn 13, Issue 1, 2011, Pages 111-120

  Zhou, Qingyu ^a   Gallo, James M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Anticancer drugs; Drug discovery and development; Pharmacokinetic pharmacodynamic model; Physiologically based pharmacokinetic model

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; FLUOROURACIL; GEFITINIB; GENISTEIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCLONAL ANTIBODY; PROTEIN C FOS; PROTEIN KINASE B; PROTEIN P185; PROTEIN TYROSINE KINASE; RAF PROTEIN; STAT3 PROTEIN; TANESPIMYCIN; TEMOZOLOMIDE;

ANTINEOPLASTIC ACTIVITY; COMPARTMENT MODEL; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG RESEARCH; DRUG TISSUE LEVEL; ENZYME INHIBITION; EXPERIMENTAL MODEL; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MATHEMATICAL MODEL; NONHUMAN; PREDICTION; QUANTITATIVE ANALYSIS; SHORT SURVEY;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; DRUG DESIGN; HUMANS; MODELS, STATISTICAL; NEOPLASMS; SYSTEMS BIOLOGY; TRANSLATIONAL MEDICAL RESEARCH;

EID: 79951997839     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-011-9253-1     Document Type: Short Survey

References (70)

1. Hanahan D,Weinberg RA. Hallmarks of cancer. Cell. 2000;100:57-70.
2. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009;458:719-24.
3. Collins I, Workman P. New approaches to molecular cancer therapeutics. Nat Chem Biol. 2006;2:689-700. (Pubitemid 44764211)
4. van Montfort R, Workman P. Structure-based design of molecular cancer therapeutics. Trends Biotechnol. 2009;27:315-28.
5. Tothfalusi L, Speidl S, Endrenyi L. Exposure-response analysis reveals that clinically important toxicity difference can exist between bioequivalent carbamazepine tablets. Br J Clin Pharmacol. 2008;65:110-22. (Pubitemid 350265172)
6. Kimko HC, Reele SS, Holford NH, Peck CC. Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model. Clin Pharmacol Ther. 2000;68:568-77.
7. Zhou Q, Guo P, Kruh GD, Vicini P, Wang X, Gallo JM. Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition. Clin Cancer Res. 2007;13:4271-9. (Pubitemid 47105992)
8. Wang S, Zhou Q, Gallo JM. Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib. Mol Cancer Ther. 2009;8:1438-47.
9. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker; 1982.
10. Rowland M, Balant L, Peck C. AAPS J. Physiologically based pharmacokinetics in Drug Development and Regulatory Science: a workshop report (Georgetown University, Washington, DC, May 29-30, 2002). 2004;6:56-67.
11. Gerlowski LE, Jain RK. Physiologically based pharmacokinetic modeling: principles and applications. J Pharm Sci. 1983;72:1103-27. (Pubitemid 13013622)
12. Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci. 2005;94:1259-76. (Pubitemid 40904190)
13. Lavé T, Parrott N, Grimm HP, Fleury A, Reddy M. Challenges and opportunities with modelling and simulation in drug discovery and drug development. Xenobiotica. 2007;37:1295-310. (Pubitemid 350035528)
14. Rocchetti M, Del Bene F, Germani M, Fiorentini F, Poggesi I, Pesenti E, et al. Testing additivity of anticancer agents in preclinical studies: a PK/PD modelling approach. Eur J Cancer. 2009;45:3336-46.
15. Takimoto CH. Pharmacokinetics and pharmacodynamic biomarkers in early oncology drug development. Eur J Cancer. 2009;45 Suppl 1:436-8.
16. Yap TA, Sandhu SK, Workman P, de Bono JS. Envisioning the future of early anticancer drug development. Nat Rev Cancer. 2010;10:514-23.
17. Kristjansen PE, Brown TJ, Shipley LA, Jain RK. Intratumor pharmacokinetics, flow resistance, and metabolism during gemcitabine infusion in ex vivo perfused human small cell lung cancer. Clin Cancer Res. 1996;2:359-67. (Pubitemid 26074622)
18. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure-an obstacle in cancer therapy. Nat Rev Cancer. 2004;4:806-13. (Pubitemid 39331152)
19. Ruenraroengsak P, Cook JM, Florence AT. Nanosystem drug targeting: facing up to complex realities. J Control Release. 2010;141:265-76.
20. Laplanche R, Meno-Tetang GM, Kawai R. Physiologically based pharmacokinetic (PBPK) modeling of everolimus (RAD001) in rats involving non-linear tissue uptake. J Pharmacokinet Pharmacodyn. 2007;34:373-400. (Pubitemid 46873032)
21. Zager MG, Schlosser PM, Tran HT. A delayed nonlinear PBPK model for genistein dosimetry in rats. Bull Math Biol. 2007;69 (1):93-117. (Pubitemid 46155346)
22. Bradshaw-Pierce EL, Eckhardt SG, Gustafson DL. A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man. Clin Cancer Res. 2007;13:2768-76. (Pubitemid 46788046)
23. Shah DK, Shin BS, Veith J, Tóth K, Bernacki RJ, Balthasar JP. Use of an anti-vascular endothelial growth factor antibody in a pharmacokinetic strategy to increase the efficacy of intraperitoneal chemotherapy. J Pharmacol Exp Ther. 2009;329:580-91.
24. Li M, Al-Jamal KT, Kostarelos K, Reineke J. Physiologically based pharmacokinetic modeling of nanoparticles. ACS Nano. 2010;4:6303-17.
25. Xu L, Eiseman JL, Egorin MJ, D'Argenio DZ. Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17- (allylamino)-17- demethoxygeldanamycin and its active metabolite in tumor-bearing mice. J Pharmacokinet Pharmacodyn. 2003;30:185-219. (Pubitemid 37176045)
26. Gupta N, Saleem A, Kötz B, Osman S, Aboagye EO, Phillips R, et al. Carbogen and nicotinamide increase blood flow and 5-fluorouracil delivery but not 5-fluorouracil retention in colorectal cancer metastases in patients. Clin Cancer Res. 2006;12:3115-23. (Pubitemid 43837359)
27. Saleem A, Price PM. Early tumor drug pharmacokinetics is influenced by tumor perfusion but not plasma drug exposure. Clin Cancer Res. 2008;14:8184-90.
28. Kety SS, Schmidt CF. The nitrous oxide method for the quantitative determination of cerebral blood flow in man. Theory, procedure and normal values. J Clin Invest. 1948;27:476-83.
29. Poulin P, Theil FP. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J Pharm Sci. 2002;91:1358-70. (Pubitemid 34651198)
30. Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci. 2006;95:1238-57. (Pubitemid 43874439)
31. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993;10:1093-5. (Pubitemid 23211439)
32. Silva AC, Kim SG, Garwood M. Imaging blood flow in brain tumors using arterial spin labeling. Magn Reson Med. 2000;44:169-73. (Pubitemid 30614774)
33. Dedrick RL, Zaharko DS, Bender RA, Bleyer WA, Lutz RJ. Pharmacokinetic considerations on resistance to anticancer drugs. Cancer Chemother Rep. 1975;59:795-804.
34. Lutz RJ, Dedrick RL, Straw JA, Hart MM, Klubes P, Zaharko DS. The kinetics of methotrexate distribution in spontaneous canine lymphosarcoma. J Pharmacokinet Biopharm. 1975;3:77-97.
35. Weissbrod JM, Jain RK, Sirotnak FM. Pharmacokinetics of methotrexate in leukemia cells: effect of dose and mode of injection. J Pharmacokinet Biopharm. 1978;6:487-503.
36. Gallo JM, Etse JT, Doshi KJ, Boudinot FD, Chu CK. Hybrid pharmacokinetic models to describe anti-HIV nucleoside brain disposition following parent and prodrug administration in mice. Pharm Res. 1991;8:247-53.
37. Devineni D, Klein-Szanto A, Gallo JM. In vivo microdialysis to characterize drug transport in brain tumors: analysis of methotrexate uptake in rat glioma-2 (RG-2)-bearing rats. Cancer Chemother Pharmacol. 1996;38:499-507.
38. Gallo JM, Vicini P, Orlansky A, Li S, Zhou F, Ma J, et al. Pharmacokinetic model-predicted anticancer drug concentrations in human tumors. Clin Cancer Res. 2004;10:8048-58. (Pubitemid 39587546)
39. Wang S, Guo P, Wang X, Zhou Q, Gallo JM. Preclinical pharmacokinetic/ pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models. Mol Cancer Ther. 2008;7:407-17. (Pubitemid 351302534)
40. Ostermann S, Csajka C, Buclin T, Leyvraz S, Lejeune F, Decosterd LA, et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res. 2004;10:3728-36. (Pubitemid 38697606)
41. Portnow J, Badie B, Chen M, Liu A, Blanchard S, Synold TW. The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation. Clin Cancer Res. 2009;15:7092-8.
42. Lu JF, Eppler SM,Wolf J, Hamilton M, Rakhit A, Bruno R, et al. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with nonsmall cell lung cancer. Clin Pharmacol Ther. 2006;80:136-45. (Pubitemid 44160689)
43. Joerger M, Huitema AD, Huizing MT, Willemse PH, de Graeff A, Rosing H, et al. Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study. Br J Clin Pharmacol. 2007;64:622-33. (Pubitemid 47568820)
44. Zandvliet AS, Schellens JH, Dittrich C, Wanders J, Beijnen JH, Huitema AD. Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin. Br J Clin Pharmacol. 2008;66:485-97.
45. Fetterly GJ, Grasela TH, Sherman JW, Dul JL, Grahn A, Lecomte D, et al. Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposomeentrapped paclitaxel. Clin Cancer Res. 2008;14:5856-63.
46. La Rosée P, O'Dwyer ME, Druker BJ. Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective. Leukemia. 2002;16:1213-9.
47. Mager DE, Wyska E, Jusko WJ. Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos. 2003;31:510-8. (Pubitemid 36444157)
48. Jusko WJ, Ko HC. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther. 1994;56:406-19. (Pubitemid 24339087)
49. Sheiner LB, Verotta D. Further notes on physiologic indirect response models. Clin Pharmacol Ther. 1995;58:238-40.
50. Luo FR, Yang Z, Dong H, Camuso A, McGlinchey K, Fager K, et al. Prediction of active drug plasma concentrations achieved in cancer patients by pharmacodynamic biomarkers identified from the geo human colon carcinoma xenograft model. Clin Cancer Res. 2005;11:5558-65. (Pubitemid 41060833)
51. Sung JH, Dhiman A, Shuler ML. A combined pharmacokineticpharmacodynamic (PK-PD) model for tumor growth in the rat with UFT administration. J Pharm Sci. 2009;98:1885-904.
52. Koch G, Walz A, Lahu G, Schropp J. Modeling of tumor growth and anticancer effects of combination therapy. J Pharmacokinet Pharmacodyn. 2009;36:179-97.
53. Dagnino G, Donelli MG, Colombo T, Bertello C, Pacciarini MA, Martini A. Pharmacodynamic model describing the growth of a mammary carcinoma in the mouse under the influence of adriamycin treatment. Oncology. 1981;38:53-8. (Pubitemid 11240618)
54. Bueno L, de Alwis DP, Pitou C, Yingling J, Lahn M, Glatt S, et al. Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. Eur J Cancer. 2008;44:142-50. (Pubitemid 350256941)
55. Tham LS, Wang L, Soo RA, Lee SC, Lee HS, Yong WP, et al. A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine+carboplatin in non-small cell lung cancer patients. Clin Cancer Res. 2008;14:4213-8.
56. Salphati L, Wong H, Belvin M, Bradford D, Edgar KA, Prior WW, et al. Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel PI3K inhibitor 2-(1H-indazol-4-yl)-6-(4- methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941). Drug Metab Dispos. 2010;38:1436-42.
57. Soto E, Staab A, Freiwald M, Munzert G, Fritsch H, Döge C, et al. Prediction of neutropenia-related effects of a new combination therapy with the anticancer drugs BI 2536 (a Plk1 inhibitor) and pemetrexed. Clin Pharmacol Ther. 2010;88:660-7.
58. Baxter LT, Zhu H, Mackensen DG, Jain RK. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res. 1994;54:1517-28. (Pubitemid 24106416)
59. Baxter LT, Zhu H, Mackensen DG, Butler WF, Jain RK. Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res. 1995;55:4611-22.
60. Ferl GZ, Kenanova V, Wu AM, DiStefano 3rd JJ. A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments. Mol Cancer Ther. 2006;5:1550-8. (Pubitemid 44070492)
61. Urva SR, Yang VC, Balthasar JP. Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibody. J Pharm Sci. 2010;99:1582-600.
62. Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006;11:81-8. (Pubitemid 43227856)
63. Rippe B, Haraldsson B. Transport of macromolecules across microvascular walls: the two-pore theory. Physiol Rev. 1994;74:163-219. (Pubitemid 24045677)
64. Himmelstein KJ, Lutz RJ. A review of the applications of physiologically based pharmacokinetic modeling. J Pharmacokinet Biopharm. 1979;7:127-45. (Pubitemid 9205249)
65. Mordenti J. Pharmacokinetic scale-up: accurate prediction of human pharmacokinetic profiles from animal data. J Pharm Sci. 1985;74:1097-9. (Pubitemid 15231330)
66. Tsuji A, Nishide K, Minami H, Nakashima E, Terasaki T, Yamana T. Physiologically based pharmacokinetic model for cefazolin in rabbits and its preliminary extrapolation to man. Drug Metab Dispos. 1985;13:729-39. (Pubitemid 16198580)
67. Hosseini-Yeganeh M, McLachlan AJ. Physiologically based pharmacokinetic model for terbinafine in rats and humans. Antimicrob Agents Chemother. 2002;46:2219-28. (Pubitemid 34665919)
68. Brightman FA, Leahy DE, Searle GE, Thomas S. Application of a generic physiologically based pharmacokinetic model to the estimation of xenobiotic levels in human plasma. Drug Metab Dispos. 2006;34:94-101. (Pubitemid 43042650)
69. Mager DE, Woo S, Jusko WJ. Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. Drug Metab Pharmacokinet. 2009;24:16-24.
70. Kagan L, Abraham AK, Harrold JM, Mager DE. Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons. Pharm Res. 2010;27:920-32.